New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
NCT ID NCT07665450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from progressing longer and achieve deeper remission. Around 1,000 participants will be enrolled, and the trial is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ramantamig (a drug) plus daratumumab, compared to standard combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant, potentially delaying disease progression.
What could go wrong
This is a large phase 3 trial, but it hasn't started yet. The new drug combination may not prove better than existing treatments, and side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••